Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Treasury Shares (2021 - 2025)

Historic Treasury Shares for Biofrontera (BFRI) over the last 5 years, with Q3 2025 value amounting to $412500.0.

  • Biofrontera's Treasury Shares fell 833.33% to $412500.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $412500.0, marking a year-over-year decrease of 833.33%. This contributed to the annual value of $450000.0 for FY2024, which is 933198.49% up from last year.
  • According to the latest figures from Q3 2025, Biofrontera's Treasury Shares is $412500.0, which was down 833.33% from $450000.0 recorded in Q2 2025.
  • In the past 5 years, Biofrontera's Treasury Shares registered a high of $343.5 million during Q2 2022, and its lowest value of $4771.0 during Q2 2023.
  • Moreover, its 5-year median value for Treasury Shares was $343512.0 (2022), whereas its average is $24.7 million.
  • Per our database at Business Quant, Biofrontera's Treasury Shares plummeted by 9999.86% in 2023 and then skyrocketed by 933198.49% in 2024.
  • Biofrontera's Treasury Shares (Quarter) stood at $8504.0 in 2021, then skyrocketed by 101.98% to $17176.0 in 2022, then plummeted by 72.22% to $4771.0 in 2023, then surged by 9331.98% to $450000.0 in 2024, then fell by 8.33% to $412500.0 in 2025.
  • Its Treasury Shares stands at $412500.0 for Q3 2025, versus $450000.0 for Q2 2025 and $450000.0 for Q1 2025.